Francisco José Cimas-rekin lankidetzan egindako argitalpenak (8)

2022

  1. ERK5 Is a Major Determinant of Chemical Sarcomagenesis: Implications in Human Pathology

    Cancers, Vol. 14, Núm. 14

2021

  1. In silico transcriptomic mapping of integrins and immune activation in Basal-like and HER2+ breast cancer

    Cellular Oncology, Vol. 44, Núm. 3, pp. 569-580

  2. Transcriptomic Correlates of Immunologic Activation in Head and Neck and Cervical Cancer

    Frontiers in Oncology, Vol. 11

  3. Transcriptomic profiles of cd47 in breast tumors predict outcome and are associated with immune activation

    International Journal of Molecular Sciences, Vol. 22, Núm. 8

2020

  1. An overview of antibody conjugated polymeric nanoparticles for breast cancer therapy

    Pharmaceutics, Vol. 12, Núm. 9, pp. 1-20

  2. Antibody conjugation of nanoparticles as therapeutics for breast cancer treatment

    International Journal of Molecular Sciences, Vol. 21, Núm. 17, pp. 1-21

  3. Genomic Signatures of Immune Activation Predict Outcome in Advanced Stages of Ovarian Cancer and Basal-Like Breast Tumors

    Frontiers in Oncology, Vol. 9

  4. Genomic mapping identifies mutations in ryr2 and ahnak as associated with favorable outcome in basal-like breast tumors expressing pd1/pd-l1

    Cancers, Vol. 12, Núm. 8, pp. 1-15